EMD Serono, Drug Prices & Medicare Spending
EMD Serono manufactures 2 drugs tracked by Medicare Part D with total spending of $357.0M.
EMD Serono Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Rebif | Interferon Beta-1a (SC) | $4,875.00 | Yes |
| 2 | Tepmetko | Tepotinib | $15,375.00 | Yes |
Frequently Asked Questions
EMD Serono manufactures 2 drugs tracked by Medicare Part D, with total annual spending of $357.0M.
Tepmetko (Tepotinib) is the most expensive at $15,375.00 per claim.
2 of 2 EMD Serono drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Source: CMS Medicare Part D Spending, 2026.